Big Pharma Pacts Benefit From Reduced HBV Biologics Competition
Aligos Candidate Bites The Dust
Executive Summary
Partnerships between big pharma and biotech focused on biologic therapies for hepatitis B could reap the benefit of less competition as lone biotechs, such as Aligos, discontinue their candidates.
You may also be interested in...
Arrowhead Eager To Take On ‘Straightforward’ NASH Approach Abandoned By J&J
J&J pipeline review results in return of PNPLA3-targeted NASH candidate optioned under 2018 alliance, but the fate of a hepatitis B candidate included in that deal is undetermined so far.
VBI Poised To Take On GSK, Dynavax As Hep B Vaccination Market Takes Off
VBI Vaccines obtained FDA approval of its three-antigen hepatitis B vaccine PreHevbrio and will take on GSK’s Engerix-B and Dynavax’s Heplisav-B as CDC recommends universal HBV immunization.
CDC Panel Stops Shy Of Universal Adult Hepatitis B Vaccine Recommendation
ACIP working group proposal for all adults was altered to include an upper age limit for universal hepatitis B vaccination.